Compare RCUS & VIRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCUS | VIRT |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2018 | 2015 |
| Metric | RCUS | VIRT |
|---|---|---|
| Price | $20.11 | $38.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 7 |
| Target Price | $28.89 | ★ $42.71 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 02-24-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.51% |
| EPS Growth | N/A | ★ 72.73 |
| EPS | N/A | ★ 5.13 |
| Revenue | $240,000,000.00 | ★ $2,845,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.89 |
| P/E Ratio | ★ N/A | $7.45 |
| Revenue Growth | N/A | ★ 28.29 |
| 52 Week Low | $6.50 | $31.55 |
| 52 Week High | $26.40 | $45.77 |
| Indicator | RCUS | VIRT |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 57.60 |
| Support Level | $20.79 | $37.14 |
| Resistance Level | $22.29 | $42.08 |
| Average True Range (ATR) | 1.13 | 1.27 |
| MACD | -0.20 | 0.06 |
| Stochastic Oscillator | 0.45 | 36.89 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.